Dynamic Chart
Alliance Pharma Delists from London Bourse's AIM After Acquisition 05-15 MT
Aegros Bidco Completes Takeover of Alliance Pharma 05-14 MT
Alliance Pharma Says Aegros Bidco Recommends Acquisition Of Alliance Pharma 05-14 RE
Alliance Pharma plc Announces the Termination of Camillo Pane as Director, Effective May 14, 2025 05-13 CI
Alliance Pharma plc Announces the Termination of Mr. Richard Alexander Mckenzie as Director, Effective from May 14, 2025 05-13 CI
Alliance Pharma Plc Announces the Termination of Martin Sutherland as Director, Effective May 14, 2025 05-13 CI
Alliance Pharma plc Announces the Termination of Kristof Leon Neirynck as Director, Effective from May 14, 2025 05-13 CI
Alliance Pharma plc Announces the Termination of Richard Crispin Jones as Director, Effective from May 14, 2025 05-13 CI
Alliance Pharma Plc Announces the Termination of Eva-Lotta Saga Sjostedt as Director, Effective May 14, 2025 05-13 CI
An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. and an undisclosed buyer completed the acquisition of remaining 71.9% stake in Alliance Pharma plc from Andrew Franklin, Richard Jones, Nick Sedgwick, Slater Investments Limited and others. 05-13 CI
Aegros' Takeover of Alliance Pharma Sanctioned by Court 05-13 MT
Slater Investments Discloses 4.37% Stake In Alliance Pharma As Of 25-Apr-2025 04-29 RE
Alliance Pharma loss narrows in 2024 due to reduced impairment charges 04-08 AN
More news
Manager TitleAgeSince
Director of Finance/CFO 59 27/09/2015
Investor Relations Contact - 31/12/2021
Human Resources Officer - 31/10/2023
Director TitleAgeSince
Director/Board Member 59 27/09/2015
Director/Board Member 59 31/12/2018
Director/Board Member 47 30/11/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.13%-2.42%+8.71%+107.71% 45.86B
-0.86%-2.33%+13.94%+63.51% 26.17B
+2.36%-0.12%+36.31% - 22.42B
-0.36%-0.84%-4.26%+63.77% 14.06B
+0.07%-2.39%-13.63%+185.46% 11.16B
+0.66%-3.71%+71.96%+79.62% 7.53B
-.--%+0.14% - - 6.79B
+0.26%+1.06%+35.71%+103.86% 6.68B
-.--%-1.95% - - 5.73B
Average +0.19%-2.20%+21.25%+100.66% 16.27B
Weighted average by Cap. +0.14%-2.12%+16.03%+97.45%
See all sector performances
Logo Alliance Pharma plc
Alliance Pharma plc is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments include Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include the Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Aloclair Plus Spray, Aloclair Plus Mouthwash, Anbesol Adult Strength Gel, Anbesol Teething Gel, Anbesol Liquid, Atopiclair Cream, and Atopiclair Lotion. It holds marketing rights to around 80 consumer healthcare brands and prescription medicines, which are sold worldwide in more than 100 countries.
Employees
290
More about the company